FY2028 EPS Estimates for Insulet Raised by Leerink Partnrs

Insulet Co. (NASDAQ:PODD) – Investment analysts at Leerink Partnrs increased their FY2028 earnings per share (EPS) estimates for Insulet in a research note issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now expects that the medical instruments supplier will post earnings of $7.80 per share for the year, up from their previous forecast of $7.75. The consensus estimate for Insulet’s current full-year earnings is $3.22 per share.

Other equities research analysts have also issued reports about the stock. Morgan Stanley lifted their price target on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Sanford C. Bernstein assumed coverage on Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price on the stock. Citigroup upped their target price on Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st. Canaccord Genuity Group lifted their price target on Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Finally, Piper Sandler increased their price objective on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Stock Performance

Shares of Insulet stock opened at $266.92 on Wednesday. The firm has a market capitalization of $18.72 billion, a P/E ratio of 45.70, a P/E/G ratio of 4.08 and a beta of 1.22. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet has a 52 week low of $160.19 and a 52 week high of $279.40. The firm’s 50 day moving average is $242.59 and its two-hundred day moving average is $212.36.

Hedge Funds Weigh In On Insulet

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Baillie Gifford & Co. increased its holdings in shares of Insulet by 20.7% in the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after purchasing an additional 389,639 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Insulet by 1.3% during the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock worth $403,339,000 after buying an additional 22,850 shares in the last quarter. Clearbridge Investments LLC grew its position in Insulet by 6.0% during the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock worth $270,364,000 after buying an additional 75,526 shares during the period. American Century Companies Inc. increased its holdings in Insulet by 18.7% in the second quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier’s stock valued at $178,728,000 after buying an additional 139,246 shares in the last quarter. Finally, Westfield Capital Management Co. LP boosted its stake in shares of Insulet by 27.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after acquiring an additional 163,388 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.